Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Yilport in connection with Infranode’s investment in Yilport Sweden
Mandate

Vinge advises Yilport in connection with Infranode’s investment in Yilport Sweden

April 03, 2019 Banking and Finance

Vinge has advised Yilport Holding AS and Yilport Sweden Terminal Investments AB (“Yilport Sweden”) in connection with a SEK 400,000,000 investment in Yilport Sweden by Infranode I (NO. 1) AB.

Yilport Sweden and its subsidiaries conduct business, inter alia, as port operator of the Port of Gävle and were, prior to the investment, wholly owned subsidiaries of Yilport Holding AS.

Vinge’s team consisted primarily of Albert Wållgren, André Isacson and Stephanie Stiernstedt (Banking and Finance) as well as Matthias Pannier, Rasmus Perdahl, Elsie Nassar and Hannes Pettersson (M&A).

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026